Roche Holding AG RHHBF
479.71 USD -15.29 (-3.09%)
At closeNov 10, 2026, 4:00 PM EST
490.00 Day range 490.00
367.19 52-week range 514.08
- YTD
- +7.65%
- 1 year
- +41.09%
- Market cap
- 382.22B
- EPS (ttm)
- 19.93
- P/E ratio
- 24.07
- YTD return
- +7.65%
- 1-year return
- +41.09%
- Volume
- 5
- Avg volume
- 92
- Open
- 490.00
- Previous close
- 495.00
- Day's range
- 490.00 – 490.00
- 52-week range
- 367.19 – 514.08
- Earnings date
- Jul 23, 2026
5D -10.29 (-2.10%)
Next earnings
Jul 23, 2026
Expected Jul 23, 2026. Consensus EPS estimate 12.51.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jul 23, 2026 | Jun 30, 2026 | 12.51 | — | — | — |
| Jan 29, 2026 | Dec 31, 2025 | 10.83 | 10.56 | -0.27 | -2.49% |
| Jul 24, 2025 | Jun 30, 2025 | 13.18 | 5.81 | -7.37 | -55.92% |
| Jan 30, 2025 | Dec 31, 2024 | 9.25 | 2.77 | -6.48 | -70.05% |
| Oct 23, 2024 | Jun 30, 2024 | 10.42 | 8.71 | -1.71 | -16.41% |
| Apr 26, 2024 | Dec 31, 2023 | 10.07 | 6.34 | -3.73 | -37.04% |
News
Perficient Expands Its Innovation Center to Advance Roche Diagnostics' Molecular Laboratory Systems 
Roche receives FDA 510(k) clearance for new cobas® eplex respiratory pathogen panel 3, enabling labs to customize respiratory testing for local patient needs 
Roche: Valuation Leaves Limited Upside 
Brown Advisory Flexible Equity Strategy: Q3 2026 Top Contributors And Detractors 
Roche Targets Emerging Oncology Market With New Lung-Cancer Drug 
Roche says divarasib cut risk of death 44% in lung cancer trial 
Genentech's Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer 
Roche's divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer 
Genentech Presents Interim Phase III Data Showing Sefaxersen Significantly Reduced Proteinuria in People With IgA Nephropathy (IgAN) 
Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
Your note
Sign in to keep a note on RHHBF — it syncs with the Stock Master app.